In this featured collection, we put a spotlight on medication assisted treatment (MAT) for opioid use disorder (OUD). Research has proven that MAT is an evidence-based strategy for treating individuals with OUD; individuals who use MAT as part of their treatment and recovery plan are more likely to be retained in treatment and to have fewer adverse events such as opioid overdose and opioid overdose mortality. In this collection we present materials from the National Academies of Science, Engineering and Medicine’s 2019 report Medications for Opioid Use Disorder Save Lives, reports on MAT from the Substance Abuse and Mental Health Services Administration and the National Institute on Drug Abuse, and a report from the New England Comparative Effectiveness Public Advisory Council on extended release medications for OUD. In addition, there is link to a summary of research that looked at whether it was possible to incorporate MAT into 12-step oriented treatment facilities.
We have also compiled materials related to MAT for the following audiences:
- Patients and caregivers
- Health care providers
- Policy makers and community leaders interested in expanding access to MAT in their communities
- Resources addressing negative sterotypes or stigma about MAT
- Guides to creating MAT programs in the following settings:
This one page document summarizes the conclusions of the 2019 National Academies report on medications for opioid use disorder.
This four page document presents the highlights from the 2019 National Academies report on medication assisted treatment for opioid use disorder. Funding Source: National Institute on Drug Abuse, National Institutes of Health; Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services
From this website, the National Academies of Medicine 2019 report “Medications for Opioid Use Disorder Save Lives” can be downloaded for free. Also available are a press release, executive summaries of the report’s conclusions and highlights, and a social media toolkit for dissemination.
This 47 page report on medications to treat opioid use disorder (OUD) includes information on how the medications work, what the diversion risk is for these medications, how medications affect HIV or hepatitis C outcomes, whether medications are offered in the criminal justice system or military, medications and
This 2018 report from the Institute for Clinical and Economic Review compared the evidence for effectiveness and value of new extended-release medications for opioid use disorder (two buprenorphine injections, one buprenorphine implant, and naltrexone injection).
SAMHSA’s 2018 Treatment Improvement Protocol is a comprehensive discussion of medication assisted treatment for opioid use disorder. This 322 page report includes sections targeted to healthcare providers and addiction treatment professionals, policy makers, and patients and their families.
A review of studies on barriers or facilitators to use of medication assisted treatment (MAT) for opioid use disorder (OUD) from the Veteran’s Health Administrations Evidence Synthesis Program. The use of MAT to treat OUD is an evidence-based practice that is often not implemented in real world settings.
Traditional 12-step, abstinence based substance use disorder treatment programs have generally rejected the use of medication assisted treatment (MAT) for opioid use disorder (OUD). The Recovery Research Institute provides a plain-language summary of research that looked at whether it was possible to incorporate MAT into the treatment services offered by a leading 12-step oriented treatment facility.
This collection features resources for patients and caregivers about medication assisted treatment (MAT) for opioid use disorder (OUD), including a guide from Partnership for Drug-Free Kids on MAT for teens and young adults with OUD.
This collection provides information about MAT specifically for health care providers.
This collection features resources for state and community leaders interested in implementing medication assisted treatment (MAT) programs for opioid use disorder (OUD) in their communities.
Despite the overwhelming evidence that medications such as methadone, buprenorphine, and naltrexone are effective at treating opioid use disorder, objections to medication assisted treatment (MAT) are still common. The resources in this collection are intended to help dispell the myths and negative stereotypes about MAT.
Efforts to expand patient access to medication assisted treatment (MAT) for opioid use disorder (OUD) often focus on enhancing the ability of primary care providers and health care clinics to offer MAT treatment. This collection features resources intended to help primary care providers and clinic staff establish and maintain MAT programs for their patients.
Hospital inpatient care programs and emergency departments are increasingly developing policies and programs to provide medication assisted treatment (MAT) to their patients. This collection features guidelines from the Massachusetts Health & Hospital Association, resources and tools from the California American College of Emergency Physicians, and links to the Public Health Institute’s California Bridge Program and the California Health Care Foundation’s Support for Hospital Opioid Use Treatment (SHOUT) initiative.
The use of medication assisted treatment (MAT) has increasingly been adopted in justice settings including correctional facilities, re-entry programs, and treatment courts. This collection includes a 2019 overview of MAT in criminal justice settings from the Substance Abuse and Mental Health Services Administration, a report from the National Sheriff’s Association and the National Commission on Correctional Health Care on implementing MAT programs in the jail setting, a report from the Legal Action Center on MAT in treatment courts, and a report on MAT for youth and young adults with justice-involvement from the National Judicial Opioid Task Force.